Sequenom Eyes Sales Force Expansion, Reimbursement for Down Syndrome Test | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom President and CEO Harry Stylli said yesterday that the firm would work with a contract sales force organization and is targeting a sales force of 150 to 175 reps focused on the obstetrics/gynecology market in the US for its SEQureDx Down Syndrome test that it intends to launch in June.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.